PID is an ascending polymicrobial infection of the upper female genital tract — encompassing endometritis, salpingitis, oophoritis, tubo-ovarian abscess (TOA), and pelvic peritonitis — most commonly caused by Chlamydia trachomatis and Neisseria gonorrhoeae, though approximately 50% of cases involve vaginal flora anaerobes, Mycoplasma genitalium, and enteric organisms. [1-2] The CDC emphasizes maintaining a low threshold for diagnosis given the high risk of long-term reproductive sequelae. [1]
1. History
- Lower abdominal/pelvic pain — the most common complaint; characterize onset, location (typically bilateral/diffuse), severity, and radiation [2-3]
- Classic presentation: abrupt onset of severe lower abdominal pain during or shortly after menses; however, atypical milder presentations are increasingly common [2]
- Abnormal vaginal discharge (mucopurulent), intermenstrual or postcoital bleeding, dyspareunia, dysuria [2]
- Timing: onset relative to menses, new sexual partner, recent unprotected intercourse
- Important negatives: missed period (ectopic pregnancy), unilateral pain (torsion, appendicitis), urinary symptoms (UTI), GI symptoms (appendicitis, diverticulitis)
- Ask about prior STI history, number of sexual partners, contraceptive use, recent uterine instrumentation (IUD insertion, D&C) [4-5]
2. Alarm Features
- Fever >38.3°C (101°F) with pelvic pain [1]
- Peritoneal signs: guarding, rebound tenderness → concern for ruptured TOA or peritonitis [6-7]
- Hemodynamic instability (tachycardia, hypotension) → sepsis [8-9]
- Right upper quadrant pain → Fitz-Hugh–Curtis syndrome (perihepatitis) [2][10]
- Missed/overdue period → must rule out ectopic pregnancy [6]
- Recent delivery, abortion, or miscarriage with pelvic pain [6]
- Palpable adnexal mass → TOA [11]
- Failure to improve within 72 hours of outpatient antibiotics [1]
3. Medications
- Recommended outpatient regimen (CDC 2021): Ceftriaxone 500 mg IM × 1 + Doxycycline 100 mg PO BID × 14 days + Metronidazole 500 mg PO BID × 14 days [1][12]
- Recommended parenteral regimen: Ceftriaxone 1 g IV q24h (or cefotetan 2 g IV q12h, or cefoxitin 2 g IV q6h) + Doxycycline 100 mg PO/IV q12h + Metronidazole 500 mg PO/IV q12h [1]
- Fluoroquinolones are NOT recommended as first-line due to quinolone-resistant N. gonorrhoeae; may be considered only if cephalosporin allergy, low gonorrhea prevalence, and reliable follow-up [1]
- Cephalosporin allergy: parenteral clindamycin + gentamicin is an alternative [13]
- Adjunctive NSAIDs do not improve clinical outcomes [2]
- IUD does not need to be removed — removal does not hasten resolution and may delay it [2]
- All contraceptive methods can be continued during treatment [1]
- Doxycycline is contraindicated in pregnancy (use azithromycin-based alternatives)
4. Diet
- No specific dietary triggers or restrictions for PID
- Ensure adequate hydration, especially if febrile or with GI side effects from antibiotics (nausea from metronidazole/doxycycline)
- Avoid alcohol during metronidazole therapy (disulfiram-like reaction)
- Take doxycycline with food and water; avoid dairy products within 1–2 hours of dosing (chelation reduces absorption)
5. Review of Systems
- GYN: vaginal discharge (color, odor), abnormal bleeding, dyspareunia, last menstrual period
- GI: nausea, vomiting, diarrhea, anorexia (overlap with appendicitis, diverticulitis)
- Urinary: dysuria, frequency, hematuria (rule out UTI/pyelonephritis)
- Constitutional: fever, chills, malaise (systemic illness suggests severe PID/TOA)
- RUQ pain: suggests perihepatitis (Fitz-Hugh–Curtis) [2]
- Musculoskeletal: joint pain/swelling (disseminated gonococcal infection)
6. Collateral History and Family History
- Partner history: symptoms in sexual partner(s) — urethral discharge, dysuria; number of partners, new partners in past 60–90 days
- Prior STI diagnoses in patient or partner(s)
- History of sexual assault or coercion
- Social context: barriers to follow-up, medication adherence, partner treatment
- Family history is generally not contributory, though immunodeficiency states may increase susceptibility
7. Risk Factors
- Age 15–25 years (highest incidence) [2][5]
- Multiple sexual partners or new sexual partner
- Prior history of PID or STI
- Unprotected sexual intercourse
- IUD insertion within the prior 3–6 weeks (risk returns to baseline thereafter) [4][7]
- Recent uterine instrumentation (D&C, hysteroscopy, endometrial biopsy)
- Vaginal douching [4]
- Bacterial vaginosis (strongly associated) [1]
- Lower socioeconomic status
- Smoking [4]
- HIV/immunosuppression (increased risk of TOA) [2]
8. Differential Diagnosis
- Ectopic pregnancy — must rule out with β-hCG in all reproductive-age women; ~40% misdiagnosed at initial visit [14]
- Appendicitis — typically unilateral RLQ pain, positive Rovsing sign, McBurney point tenderness; PID is more diffuse/bilateral [14]
- Ovarian torsion — sudden-onset unilateral pain, nausea/vomiting, Doppler showing absent flow
- Ruptured ovarian cyst — acute onset, unilateral, often mid-cycle
- Endometriosis — chronic/cyclical pain, dysmenorrhea, dyspareunia
- Urinary tract infection/pyelonephritis — dysuria, CVA tenderness, positive UA
- Diverticulitis — typically LLQ, older patients, CT findings
- Tubo-ovarian abscess — complication of PID; suspect with adnexal mass, failure to improve on antibiotics [7][11]
9. Past Medical History
- Prior PID episodes — each episode increases risk of infertility (~8% after 1 episode, ~20% after 2, ~40% after 3) [2]
- Prior ectopic pregnancy
- History of STIs (chlamydia, gonorrhea, trichomoniasis)
- HIV status
- Diabetes mellitus or immunosuppression (increased TOA risk) [11]
- Surgical history: prior pelvic/abdominal surgery, recent uterine instrumentation
- IUD use and timing of insertion
10. Physical Exam
- Vital signs: fever >38.3°C, tachycardia (assess for sepsis)
- Abdominal exam: lower abdominal tenderness (typically bilateral/diffuse), assess for peritoneal signs (guarding, rebound), RUQ tenderness (Fitz-Hugh–Curtis) [14]
- Speculum exam: mucopurulent cervical discharge, cervical friability (positive "swab test" — yellow/green mucus on cotton swab in cervical os) [2]
- Bimanual exam — the cornerstone of diagnosis:
- Cervical motion tenderness (chandelier sign)
- Uterine tenderness
- Adnexal tenderness (unilateral or bilateral)
- Adnexal mass or fullness (suggests TOA)
- Per CDC: one or more of the three minimum criteria (CMT, uterine tenderness, adnexal tenderness) in a woman at risk is sufficient to initiate empiric treatment [1]
- Pelvic tenderness has >95% sensitivity but poor specificity; lower genital tract inflammation findings increase specificity [2]
11. Lab Studies
- Pregnancy test (urine β-hCG) — mandatory to rule out ectopic pregnancy [2]
- NAAT for N. gonorrhoeae and C. trachomatis — cervical or vaginal swab [2]
- Wet prep/saline microscopy of vaginal fluid — look for WBCs (>1 neutrophil per epithelial cell), clue cells (BV), trichomonads [1-2]
- CBC — leukocytosis supports but is not required for diagnosis
- ESR and/or CRP — elevated values increase diagnostic specificity [1-2]
- HIV and syphilis testing — recommended in all PID patients [1]
- Urinalysis — to rule out UTI
- Blood cultures if sepsis is suspected
12. Imaging
- First-line: Transvaginal ultrasound — look for thickened fluid-filled tubes (pyosalpinx/hydrosalpinx), tubo-ovarian complex/abscess, free pelvic fluid [2][15]
- Sensitivity is only fair for early PID; highly specific when positive
- Power Doppler showing tubal hyperemia is highly suggestive of infection [2]
- CT abdomen/pelvis — often the first study obtained in the ED; findings include uterosacral ligament thickening, pelvic fat stranding, reactive lymphadenopathy, free fluid, TOA [15]
- MRI — high sensitivity and specificity but expensive; reserved for diagnostic uncertainty [2]
- Imaging is unnecessary in mild, uncomplicated PID with classic presentation responding to empiric therapy
- Imaging is indicated when TOA is suspected, diagnosis is uncertain, or patient fails to improve on antibiotics
13. Special Tests
- Wet mount microscopy — point-of-care; WBC predominance in vaginal secretions is a key supporting criterion [1]
- Cervical Gram stain — may show gram-negative intracellular diplococci (gonorrhea); not sensitive enough for screening
- Endometrial biopsy — histopathologic evidence of endometritis (plasma cells, neutrophils) confirms PID; somewhat invasive and delays diagnosis; reserved for atypical cases [1-2]
- Laparoscopy — historically the reference standard for salpingitis; not routinely performed; indicated when diagnosis remains uncertain after non-invasive workup [1]
- Whiff test and vaginal pH — assess for concurrent BV
14. ECG
- ECG is not routinely indicated in uncomplicated PID
- Obtain ECG if:
- Sepsis is suspected — may show sinus tachycardia, new-onset atrial fibrillation/flutter, QT prolongation, or ST-T changes [16]
- Hemodynamic instability or concern for sepsis-induced cardiomyopathy [9][17]
- Rare case reports of C. trachomatis-associated myocarditis with severe PID/sepsis [9]
15. Assessment
- PID is a clinical diagnosis — no single test is both sensitive and specific; the positive predictive value of clinical diagnosis is 65–90% compared with laparoscopy [1]
- Severity stratification:
- Mild-moderate: ambulatory, tolerating PO, no peritoneal signs, no TOA → outpatient management
- Severe: high fever, peritoneal signs, inability to tolerate PO, TOA, sepsis → inpatient management [1-2]
- Atypical/subclinical presentations are common and increasingly recognized; most women with tubal-factor infertility have no prior PID diagnosis [2]
- Complications: chronic pelvic pain, infertility (~8% per episode), ectopic pregnancy, TOA, peritonitis, Fitz-Hugh–Curtis syndrome, septic thrombophlebitis [7][15]
16. Treatment Plan
Outpatient (mild-moderate PID)
- Ceftriaxone 500 mg IM × 1 + Doxycycline 100 mg PO BID × 14 days + Metronidazole 500 mg PO BID × 14 days [1]
- Alternative: Cefoxitin 2 g IM × 1 + Probenecid 1 g PO × 1, then doxycycline + metronidazole as above [1]
Inpatient (severe PID)
- Ceftriaxone 1 g IV q24h + Doxycycline 100 mg PO q12h + Metronidazole 500 mg IV/PO q12h [1]
- Or: Cefotetan 2 g IV q12h + Doxycycline 100 mg PO q12h [1]
- Or: Cefoxitin 2 g IV q6h + Doxycycline 100 mg PO q12h [1]
- Transition to oral therapy after 24–48 hours of clinical improvement; complete 14 days total [1]
- TOA: >24 hours inpatient observation recommended; clindamycin + aminoglycoside may be particularly appropriate; percutaneous drainage if failing antibiotics [1-2][8]
Partner treatment
- All sex partners within the prior 60 days should be treated empirically; expedited partner therapy where legal [13][18]
- Abstain from intercourse until therapy is complete, symptoms resolved, and partners treated [1]
17. Disposition
Admission criteria: [1-2][12]
- Pregnancy
- Severe illness (high fever, nausea/vomiting, inability to tolerate PO)
- Tubo-ovarian abscess
- Surgical emergency cannot be excluded (appendicitis, torsion)
- Failed outpatient therapy (no improvement within 72 hours)
Discharge criteria
- Mild-moderate symptoms, tolerating PO, reliable follow-up, no peritoneal signs, no TOA
- Able to complete 14-day antibiotic course
Specialist consultation triggers
- OB/GYN: TOA, diagnostic uncertainty, surgical abdomen, failed medical therapy
- Infectious disease: cephalosporin allergy, quinolone-resistant gonorrhea, complex polymicrobial infections [1]
18. Follow-Up / Return Precautions
- Follow-up within 72 hours of initiating outpatient therapy to assess clinical improvement (defervescence, reduction in tenderness) [1]
- If no improvement within 72 hours → hospitalization, IV antibiotics, and additional diagnostics including consideration of laparoscopy [1]
- Retest for chlamydia and gonorrhea at 3 months regardless of partner treatment status [1]
- Counsel on completion of the full 14-day antibiotic course even if symptoms improve
- Return precautions — seek immediate care for:
- Worsening abdominal pain or new peritoneal signs
- High fever, rigors, or inability to keep medications down
- Syncope or lightheadedness
- Counsel on STI prevention: consistent condom use, limiting number of partners, screening recommendations (annual chlamydia/gonorrhea screening for women <25 years) [18]
- Approximately one-third of adolescents with PID experience recurrent STI/PID within 4 years, underscoring the need for sustained risk-reduction counseling [19]
References
1. Sexually Transmitted Infections Treatment Guidelines, 2021. — Workowski KA, Bachmann LH, Chan PA, et al. MMWR. Recommendations and Reports : Morbidity and Mortality Weekly Report. Recommendations and Reports. 2021.
2. Pelvic Inflammatory Disease. — Brunham RC, Gottlieb SL, Paavonen J. The New England Journal of Medicine. 2015.
3. Antibiotic Therapy for Pelvic Inflammatory Disease. — Savaris RF, Fuhrich DG, Maissiat J, Duarte RV, Ross J. The Cochrane Database of Systematic Reviews. 2020.
4. Moxifloxacin monotherapy for treatment of uncomplicated pelvic inflammatory disease: A systematic review and meta‐analysis with trial sequential analysis of randomized controlled trials. — Chen F, Dong Q, Hong W, Zhao J, Li Y. Pharmacoepidemiology and Drug Safety. 2023.
5. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). — Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024.
6. Targeted Point-of-Care Testing Compared With Syndromic Management of Urogenital Infections in Women (WISH): A Cross-Sectional Screening and Diagnostic Accuracy Study. — Verwijs MC, Agaba SK, Sumanyi JC, et al. The Lancet. Infectious Diseases. 2019.
7. Interventions in Addition to Broad-Spectrum Intravenous Antibiotic Therapy for the Treatment of Radiologically Proven Tubo-Ovarian Abscess. — Boyens H, Bofill Rodriguez M, Wimsett J, et al. The Cochrane Database of Systematic Reviews. 2025.
8. Identification and Treatment of Acute Pelvic Inflammatory Disease and Associated Sequelae. — Frock-Welnak DN, Tam J. Obstetrics and Gynecology Clinics of North America. 2022.
9. Severe Sepsis and Acute Myocardial Dysfunction in an Adolescent With Chlamydia Trachomatis Pelvic Inflammatory Disease: A Case Report. — Morgan AM, Roden RC, Matson SC, et al. Journal of Pediatric and Adolescent Gynecology. 2018.
10. The Management of Intra-Abdominal Infections From a Global Perspective: 2017 WSES Guidelines for Management of Intra-Abdominal Infections. — Sartelli M, Chichom-Mefire A, Labricciosa FM, et al. World Journal of Emergency Surgery : WJES. 2017.
11. High Risk and Low Prevalence Diseases: Tubo-Ovarian Abscess. — Bridwell RE, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.
12. Sexually Transmitted Infections: Updated Guideline From the CDC. — Klein DA, Valerio CR, Cofield ZN. American Family Physician. 2022.
13. Diagnosis and Treatment of Sexually Transmitted Infections: A Review. — Tuddenham S, Hamill MM, Ghanem KG. The Journal of the American Medical Association. 2022.
14. Evaluation of Acute Pelvic Pain in Women. — Frasca DJ, Jarrio CE, Perdue J. American Family Physician. 2023.
15. Pelvic Inflammatory Disease: Multimodality Imaging Approach With Clinical-Pathologic Correlation. — Revzin MV, Mathur M, Dave HB, Macer ML, Spektor M. Radiographics : A Review Publication of the Radiological Society of North America, Inc. 2016.
16. Association of Electrocardiogram Abnormalities With Clinical Outcomes in Emergency Department Sepsis Patients. — Kotruchin P, Chuehongthong M, Tangpaisarn T, et al. The Western Journal of Emergency Medicine. 2026.
17. Current Challenges in Understanding, Diagnosing and Managing Sepsis-Induced Cardiac Dysfunction. — Paraschiv C, Popescu Moraru MR, Paduraru LF, et al. Journal of Critical Care. 2025.
18. Pelvic Inflammatory Disease: Diagnosis, Management, and Prevention. — Curry A, Williams T, Penny ML. American Family Physician. 2019.
19. Subsequent Sexually Transmitted Infection After Outpatient Treatment of Pelvic Inflammatory Disease. — Trent M, Chung SE, Forrest L, Ellen JM. Archives of Pediatrics & Adolescent Medicine. 2008.